Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 18/20 | 1.00 |
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385284 | 1.00 | USP30 (1.00) | USP30PRCP | |
| SCHEMBL19400823 | 0.91 | USP30 (0.83) | USP30PRCP | |
| SCHEMBL29562718 | 0.91 | USP30 (0.83) | USP30PRCP | |
| SCHEMBL29562247 | 0.80 | USP30 (0.66) | USP30 | |
| SCHEMBL19385343 | 0.80 | USP30 (0.66) | USP30PRCP | |
| SCHEMBL19385344 | 0.80 | USP30 (0.66) | USP30PRCP | |
| SCHEMBL29679888 | 0.77 | USP30 (0.62) | USP30PRCP | |
| SCHEMBL29562373 | 0.76 | USP30 (0.61) | USP30 | |
| SCHEMBL29562461 | 0.75 | USP30 (0.64) | USP30 | |
| SCHEMBL29562178 | 0.75 | USP30 (0.63) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | claimed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | claimed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | claimed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | claimed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | claimed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | claimed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | claimed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | USP30 1/4885PRCP 151/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | USP30 1/4885PRCP 151/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | USP30 1/4885PRCP 151/4885 |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | USP30 1/4885PRCP 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.